Editas Medicine (EDIT) Receivables - Net (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Receivables - Net data on file, last reported at $15.2 million in Q4 2025.

• Receivables - Net for Q4 2025 came in at $15.2 million, down 6.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $15.2 million (down 6.7% YoY), and the FY2025 annual result was $15.2 million, down 6.7% from the prior year.
• Receivables - Net grew to $15.2 million in Q4 2025 per EDIT's latest filing, from $8.1 million in the prior quarter.
• Over five years, Receivables - Net peaked at $16.3 million in Q4 2024 and troughed at $120000.0 in Q3 2022.
• A 5-year average of $3.3 million and a median of $630000.0 in 2021 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2021 and 2025: Receivables - Net sank 95.59% in 2021, then surged 6352.38% in 2025.
• A 5-year view of Receivables - Net shows it stood at $267000.0 in 2021, then soared by 1826.97% to $5.1 million in 2022, then jumped by 98.0% to $10.2 million in 2023, then surged by 59.67% to $16.3 million in 2024, then declined by 6.7% to $15.2 million in 2025.
• Business Quant data shows EDIT's Receivables - Net at $15.2 million in Q4 2025, $8.1 million in Q3 2025, and $588000.0 in Q2 2025.